The potential role of ribonucleic acid methylation in the pathological mechanisms of fragile X syndrome

被引:3
|
作者
Chen, Yu-Shan [1 ,2 ]
Dong, Jing [1 ]
Tan, Wei [2 ]
Liu, Hui [1 ,2 ]
Zhang, Si-Ming [1 ,2 ]
Zou, Jia [1 ,2 ]
Chen, Yi-Qi [1 ,2 ]
Bai, Shu-Yuan [1 ,2 ]
Zeng, Yan [1 ,2 ,3 ]
机构
[1] Wuhan Univ Sci & Technol, Brain Sci & Adv Technol Inst, Sch Med, Hubei Prov Key Lab Occupat Hazard Identificat & Co, Wuhan, Peoples R China
[2] Wuhan Univ Sci & Technol, Geriatr Hosp, Wuhan, Peoples R China
[3] Wuhan Univ Sci & Technol, West Huangjiahu Rd, Wuhan 430065, Peoples R China
基金
中国国家自然科学基金;
关键词
Fragile X syndrome; RNA modification; 5-methylcytosine (m 5 C); RNA -binding protein; Synaptic function; N6-methyladenosine(m6A); MENTAL-RETARDATION PROTEIN; MESSENGER-RNA TRANSLATION; NUCLEAR EXPORT; MOUSE MODEL; M(6)A RNA; BINDING; 5-HYDROXYMETHYLCYTOSINE; IDENTIFICATION; NEURONS; RIBONUCLEOPROTEIN;
D O I
10.1016/j.bbr.2023.114586
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Fragile X syndrome (FXS) is a common inherited cause of intellectual disabilities and single-gene cause of autism spectrum disorder (ASD), resulting from the loss of functional fragile X messenger ribonucleoprotein (FMRP), an RNA-binding protein (RBP) encoded by the fragile X messenger ribonucleoprotein 1 (FMR1) gene. Ribonucleic acid (RNA) methylation can lead to developmental diseases, including FXS, through various mechanisms mediated by 5-hydroxymethylcytosine, 5-methylcytosine, N6-methyladenosine, etc. Emerging evidence suggests that modifications of some RNA species have been linked to FXS. However, the underlying pathological mechanism has yet to be elucidated. In this review, we reviewed the implication of RNA modification in FXS and summarized its specific characteristics for facilitating the identification of new therapeutic targets.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Macro Role(s) of MicroRNAs in Fragile X Syndrome?
    Xuekun Li
    Peng Jin
    NeuroMolecular Medicine, 2009, 11 : 200 - 207
  • [42] The role of microRNAs in fragile X mental retardation syndrome
    Lin, S. L.
    Ying, S. Y.
    Chang, S. J.
    JOURNAL OF NEUROCHEMISTRY, 2007, 102 : 247 - 247
  • [43] Macro Role(s) of MicroRNAs in Fragile X Syndrome?
    Li, Xuekun
    Jin, Peng
    NEUROMOLECULAR MEDICINE, 2009, 11 (03) : 200 - 207
  • [44] Pathological Crying Associated With Fragile X-Associated Tremor/Ataxia Syndrome
    Van Ballaer, Kim
    Vandenbulcke, Mathieu
    JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2014, 26 (04) : E21 - E22
  • [45] Potential Drug Therapy For Fragile X Tremor/Ataxia Syndrome
    Brown, Collis
    Sobrian, Sonya
    Hudson, Tamaro
    FASEB JOURNAL, 2022, 36
  • [46] Potential pharmacological treatment of fragile X syndrome during adulthood
    Xu, Zhao-Hui
    Zhao, Ming-Gao
    NEUROSCIENCE BULLETIN, 2009, 25 (05) : 296 - 300
  • [47] FMRP expression as a potential prognostic indicator in fragile X syndrome
    Tassone, F
    Hagerman, RJ
    Iklé, DN
    Dyer, PN
    Lampe, M
    Willemsen, R
    Oostra, BA
    Taylor, AK
    AMERICAN JOURNAL OF MEDICAL GENETICS, 1999, 84 (03): : 250 - 261
  • [48] Involvement and Therapeutic Potential of the GABAergic System in the Fragile X Syndrome
    Heulens, Inge
    D'Hulst, Charlotte
    Braat, Sien
    Rooms, Liesbeth
    Kooy, R. Frank
    THESCIENTIFICWORLDJOURNAL, 2010, 10 : 2198 - 2206
  • [49] From FMRP Function to Potential Therapies for Fragile X Syndrome
    Sethna, Ferzin
    Moon, Changjong
    Wang, Hongbing
    NEUROCHEMICAL RESEARCH, 2014, 39 (06) : 1016 - 1031
  • [50] Development of mavoglurant and its potential for the treatment of fragile X syndrome
    Gomez-Mancilla, Baltazar
    Berry-Kravis, Elizabeth
    Hagerman, Randi
    von Raison, Florian
    Apostol, George
    Ufer, Mike
    Gasparini, Fabrizio
    Jacquemont, Sebastien
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (01) : 125 - 134